Invention Grant
- Patent Title: Dual NK1/NK3 receptor antagonists
- Patent Title (中): 双NK1 / NK3受体拮抗剂
-
Application No.: US13076891Application Date: 2011-03-31
-
Publication No.: US08404708B2Publication Date: 2013-03-26
- Inventor: Torsten Hoffmann , Andreas Koblet , Jens-Uwe Peters , Patrick Schnider , Andrew Sleight , Heinz Stadler
- Applicant: Torsten Hoffmann , Andreas Koblet , Jens-Uwe Peters , Patrick Schnider , Andrew Sleight , Heinz Stadler
- Applicant Address: US NJ Nutley
- Assignee: Hoffmann-La Roche Inc.
- Current Assignee: Hoffmann-La Roche Inc.
- Current Assignee Address: US NJ Nutley
- Agent George W. Johnston; Patricia S. Rocha-Tramaloni; Kimberly J. Prior
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/47
Abstract:
The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.
Public/Granted literature
- US20110178055A1 DUAL NK1/NK3 RECEPTOR ANTAGONISTS Public/Granted day:2011-07-21
Information query
